Trial status March 2017

In Africa

The aim of the EBL2002 trial in Africa is to test the vaccine in a total of 1,188 subjects including healthy adults and population groups including the elderly, HIV-infected adults, adolescents and children. So far, 1688 participants have been screened and 858 have been randomized across Cohort 1(healthy adults), Cohort 2A (HIV-infected individuals) and Cohort 2B (healthy adolescents), of which 613 have received the boost vaccination.

In Europe

The EBL2001 trial in Europe (UK, France) aims to vaccinate a total of 630 subjects (healthy adults). So far, 423 study participants in Europe have been randomized (143 were randomized in reporting year 1 and 280 in reporting year 2), of which 290 have received the boost vaccination.

From a scientific perspective

Thanks to the finalisation of Cohort 1, the first results in EBOVAC2 on the immune response to the vaccine were obtained by the Oxford Vaccine Group (UOXF) in a subcohort of 30 participants in the UK.  During the last 12 months, UOXF has been characterising the B cell response to Ad26.ZEBOV/MVA.BN.Filo and has shown strong plasma cell responses and also identified their phenotypes. The group has also begun preliminary analysis of the antibody VH-gene response post Ad prime and MVA boost and initial isolation of monoclonal antibodies has been achieved by the Townsend group.


  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here :

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research